From cradle to twilight: The carboxyl terminus directs the fate of the A2A-adenosine receptor  by Keuerleber, Simon et al.
Biochimica et Biophysica Acta 1808 (2011) 1350–1357
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemFrom cradle to twilight: The carboxyl terminus directs the fate of the
A2A-adenosine receptor☆
Simon Keuerleber, Ingrid Gsandtner, Michael Freissmuth ⁎
Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Austria☆ This article is part of a Special Issue entitled: “Aden
⁎ Corresponding author. Institute of Pharmacology,
Währinger Straße13a,A-1090Vienna,Austria. Tel.:+4314
E-mail address: michael.freissmuth@meduniwien.ac
0005-2736/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamem.2010.05.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 April 2010
Received in revised form 5 May 2010
Accepted 5 May 2010
Available online 15 May 2010
Keywords:
A2A-adenosine receptor
Gs
ARNO
ARF6
USP4
C-terminus
ER exportThe extended carboxyl terminus of the A2A-adenosine receptor is known to engage several proteins other
than those canonically involved in signalling by GPCRs (i.e., G proteins, G protein-coupled receptor kinases/
GRKs, arrestins). The list includes the deubiquinating enzyme USP4, α-actinin, the guanine nucleotide
exchange factor for ARF6 ARNO, translin-X-associated protein, calmodulin, the neuronal calcium binding
protein NECAB2 and the synapse associated protein SAP102. However, if the fate of the A2A-receptor is taken
into account — from its birthplace in the endoplasmic reticulum to its presumed site of disposal in the
lysosome, it is evident that many more proteins must interact with the A2A-adenosine receptor. There are
several arguments that support the conjecture that these interactions will preferentially occur with the
carboxyl terminus of the A2A-adeonsine receptor: (i) the extended carboxyl terminus (of 122 residues=)
offers the required space to accommodate companions; (ii) analogies can be drawn with other receptors,
which engage several of these binding partners with their C-termini. This approach allows for deﬁning the
nature of the unknown territory. As an example, we posit a chaperone/coat protein complex-II (COPII)
exchange model that must occur on the carboxyl terminus of the receptor. This model accounts for the
observation that a minimum size of the C-terminus is required for correct folding of the receptor. It also
precludes premature recruitment of the COPII-coat to a partially folded receptor. This article is part of a
Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
Medical University of Vienna,
27764171; fax:+4312779641.
.at (M. Freissmuth).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
1.1. Accessory proteins/GPCR interacting proteins
G protein-coupled receptors (GPCRs) were originally deﬁned by
their interaction with their eponymous signalling partner, the hetero-
trimeric G proteins; they were later appreciated to share a common
structural backbone, the heptahelical arrangement of their transmem-
brane segments. Desensitization of GPCRswas also appreciated to occur
via a conservedmechanism, namely the recruitmentofGRKs (Gprotein-
coupled receptor kinases) that phosphorylated the agonist-bound
receptor and arrestins that trapped the phosphorylated receptors and
thus precluded access of the cognate G protein(s). In addition, the non-
visual arrestins (arrestin-2 and -3=β-arrestin1- and -2) serve as
adapters for recruiting the clathrin coat components and to recruit
additional signaling molecules; this allows the internalized receptor to
trigger a second wave of signals that are G protein-independent [1].
While these common properties have been clariﬁed over the past three
decades, it has also been appreciated that individual receptors differwidely in the range of physiological responses that they elicit although
they engage similar or identical signaling components (i.e., hetero-
trimeric G protein(s), GRKs and arrestins).
From a structural perspective, this observation is not surprising: there
is a large variation in the primary sequence of GPCRs; conserved elements
can be found in the hydrophobic core and in the intracellular loops.
However, it is worth noting that even the “business ends” are remarkably
divergent: the G protein interaction site is formed by the intracellular
loops and the segment adjacent to the last transmembrane helix (termed
helix 8, because it runs as short helix perpendicular to the helices of the
hydropohobic core). Sequence gazing fails to unequivocally predictwhich
heterotrimericGprotein(s) a given receptor couples to. In addition, GPCRs
differ widely in the presence or absence of additional structural elements.
Based on these they can be arranged into 5 groups termed GRAFS for
glutamate, rhodopsin, adhesion, frizzled, and secretin (based on proto-
typical representatives of individual families; see [2]. The phylogenetic
assignment of a common GPCR ancestor also proves useful when tested
on an evolutionary scale in species ranging from plants and fungi to
mammals [3]. Large differences exist in the N- and C-termini of GPCR
classes. The N-termini are extracellular and may act as additional ligand
docking site. The C-termini are of particular interest, because–in many
instances–they afford the association of GPCRswith a variety of additional
proteins that are neither heterotrimeric G proteins, GRKs or arrestins. For
lack of a better term, these proteins are referred to as accessoryproteins or
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small soluble signalling proteins (e.g., calmodulin) to peripheral mem-
brane proteins like the PDZ-containing scaffolds (e.g. PICK1 — protein
interacting with C-kinase) and transmembrane proteins (e.g., RAMP1-3,
receptor activity modifying proteins 1-3, other GPCRs) [4].
1.2. Docking to the C-terminus of the A2A-receptor
This review focuses on the A2A-adenosine receptor, which has many
unusual properties: it is amember of the rhodopsin class of GPCR's like its
closest relatives, the other three adenosine receptor — the Gi/Go-coupled
A1- and A3-adenosine receptors and the Gs/Gq-coupled A2B-adenosine
receptors [5]. In contrast to the other three adenosine receptors and in
contrast to many other GPCRs of the rhodopsin family, the A2A-receptor
has an unusually long intracellular carboxyl terminus: 122 amino acids in
the human A2A-receptor versus 40, 38 and 34 amino acids of the A2B-
receptor and of the A1- and A3-receptors, respectively (Fig. 1). The C-
terminus of theA2A-receptor also lacks the canonical cysteine at the endof
helix 8, i.e., the segment adjacent to transmembrane helix 7. One or two
cysteines are present at this position in virtually all other rhodopsin-like
GPCRs. The cysteine residue(s) represent(s) a (putative) palmitoylation
site (Fig. 1). Palmitoylation is known to mediate protein–protein
interactions and to anchor peripheral membrane proteins or protein
segments at themembrane [6]. TheC-terminus of theA2A receptormaybe
more ﬂexible because it is not constrained by a lipid anchor. These two
features, relative length and lateral ﬂexibility, may combine to afford the
interaction of the A2A receptor with many additional accessory proteins,
other than G proteins, G protein receptor kinases (GRKs) or β-arrestins.
The X-ray crystal structure of the A2A-receptor [7] visualizes helix 8 as a
folded structure up to leucine308. It is not possible to infer any additional
information about the C-terminus because residues beyond alanine317
were eliminated by truncation. In the crystal, helix 8 is stabilized by
interactions with transmembrane helix 1. The juxtamembrane segment
(helix 8 plus a few residues up to position 311) is required for proper
folding of the receptor. The rest of the C-terminus (∼100 amino acids) is
dispensable for ligand binding [7,8] and for G protein coupling [9].
It is not clear, how the conformational change induced by binding of
agonists and antagonists is relayed to the carboxyl terminus. Structural
information is only available for the antagonist-bound form of the A2A-
adenosine receptor [7]. The best studied receptor is rhodopsin: there is
little evidence that helix 8 unwinds or changes its conformation inFig. 1. The C-terminus of the human A2A-receptor compared to the C-termini of the three oth
receptor (bottom, 122 amino acids) is much longer than that of the human A1-receptor (36 a
amino acid is the R/K at the end of helix 7, i.e.: R291 in the human A1-receptor, K285 in
phenylalanine/leucine/isoleucine (FXXXFXXXLL)-related related motifs are highlighted in al
palmitoylation and which is absent in the A2A-receptor. The signiﬁcance of the dileucine mot
diacidic motif is present in mammals but is, for instance absent in the two A2A-receptors of t
by colour code in the C-terminus of the A2A-receptor.response to activation. In fact, the crystal structure of an active
(=retinal-free) opsin does not indicate any rearrangement within
helix-8 [10]. In fact, a C-terminal peptide of Gαt (the α-subunit of
transducin) is accommodated by a cavity between the transmembrane
helices while helix-8 is displaced by rigid body motion [11]. Similarly,
distance measurements by electron paramagnetic resonance also
indicate that helix 8 is maintained in light activated rhodopsin in
solution [12,13]. Beyond helix 8, the carboxyl terminus of rhodopsin
does not appear to contain any ordered structure. Regardless ofwhether
it is examined in the inactive dark state or in the light-activated
metarhodopsin-II form, the carboxyl terminus is highly ﬂexible and
mobile and reminiscent of an unfolded peptide [14]. Unfolded protein
segments are intuitively unappealing. However, they are much more
common than generally appreciated [15,16]. Assuming that a large
portion of the carboxyl terminus of the A2A-receptor is also devoid of a
rigid structure, the following mechanism can be invoked to account for
transmitting information on the activity state of the receptor to the
carboxyl terminus: the high ﬂexibility of the carboxyl terminus allows
the A2A-receptor to fold back and interact with the loops connecting the
hydrophobic transmembrane helices. By these transient interactions
segments of the carboxyl terminus may therefore sample the receptor
conformation. There is little experimental evidence to support this
conjecture for the A2A-receptor other that serial truncation reduces cell
surface expression of the receptor [7–9]. However, this issue has been
investigated more systematically with the A1-adenosine receptor:
truncation of the carboxyl terminus causes a folding problem, i.e., the
receptor is retained in the endoplasmic reticulum in an inactive, binding
incompetent state [17]. This deﬁciency can be remedied by receptor
antagonist [18] (see also below). At the very least, this provides
circumstantial evidence for a connectionbetween thehydrophobic core,
where the ligand binding site resides and the carboxyl terminus.
There are at least six accessory proteins that have beendocumented to
bind to the C-terminus [19–21] and the list is growing. Examples are (i)
the ubiquitin-speciﬁc protease 4 (USP4) [22], (ii) a guanine nucleotide
exchange factor of the small monomeric G proteins of the ADP-
ribosylation factor (ARF) family (ARNO/cytohesin-2) [23,24], (iii) trans-
lin-X-associated protein [25], (iv) α-actinin [26]. We have identiﬁed
several additional candidate proteins (e.g., Neuroendocrine-Disks large
homolog 3/Synapse-associated protein 102 (NE-DLG/ SAP102); 14.3.3
protein-θ/τ and astrin (unpublished observations). Although the C-
terminusmay exist in an extended conformation and thus provide a lot ofer G protein coupled adenosine receptors. The carboxyl terminus of the A2A-adenosine
mino acids), A3-receptor (34 amino acids) and A2B-receptors (40 amino acids). The ﬁrst
the human A3-receptor, R293 in the A2B-receptor and R291 in the A2A-receptor. The
l receptors. The arrow marks the position of the conserved cysteine, which is the site of
if is not clear, it is absent in several species orthologs (e.g., rat and cattle). Similarly, the
he zebra ﬁsh. The known binding sites for A2A-receptor interacting proteins are marked
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unlikely that the C-terminus can accommodate several partners simul-
taneously. This is exempliﬁed by the overlapping binding sites for
calmodulin, ARNOandα-actinin. Thus, individual interactions are likely to
be only transient. The presence of multiple binding sites for signalling
molecules, scaffolding proteins and adapter proteins may allow the C-
terminus of the A2A receptor to serve as a hub determining the fate of the
signalling properties of the receptor depending on the actual location of
the receptor. In addition, the carboxyl terminus of the A2A-receptor is
subject to extensive phosphorylation by protein kinase C isoforms [27].
The functional signiﬁcance of this reactionwas not understood. In view of
the many new interactors, it appears tempting to speculate that protein
kinase C-induced phosphorylation may allow for dynamic regulation of
interactions bypromoting the associationwithone typeof interactors and
abrogating interactions with other proteins.
While this collection of interaction partners may appear to be large, it
is in fact a rudimentary list that highlights the insular nature of our
knowledge: starting with its birth in the endoplasmic reticulum the A2A
receptor will meet many companions on its trajectory to the cell surface
and on its subsequent way to its site of disposal. In this review, we intend
to chart known islandsofﬁrmgroundand topoint out blank spaceswhere
interactors can be predicted.
2. From birth to rite of passage
2.1. Asssisted folding in the ER
Like all membrane proteins, GPCRs are born in the endoplasmic
reticulum. Because the N-terminus of the A2A-receptor is very short, the
ﬁrst transmembrane helix serves as a docking site for the signal
recognition particle (SRP). SRP engages this helix, arrests elongation and
targets the ribosome-nascent chain-SRP complex to the ER (endoplasmic
reticulum) membrane via a GTP-dependent interaction with the SRP
receptor [28]. Translation resumes and the receptor is inserted cotransla-
tionally into the ER through the protein-conducting channel. The latter is
formed by the Sec61 complex a conserved, heterotrimeric membrane–
protein complex. Insertion of the other 6 transmembrane helices of the
A2A-receptor is likely to proceed in a canonical way: the Sec61 channel
allows the hydrophilic portions to emerge into the lumen of the
endoplasmic reticulum, while hydrophobic transmembrane segments
exit laterally into the lipid phase [29]. This process requires also the
recruitment of BiP/Grp78 (originally identiﬁed as the binding protein of
the immunoglobulin heavy chain and as glucose regulated protein of
78 kDa, a hsp70-related ER-chaperone) to the luminal side of the
translocon-complex. This prevents leakage of the aqueous pore. It is
worthpointingout that BiP is not foundonall active transloconcomplexes
[30]. The receptor for TSH was ﬁrst shown to bind BiP [31], but a
subsequent systematic survey of all glycoprotein hormone receptors, i.e.,
the related receptors for TSH (thyrotropine), LH (luteinizing hormone)
and FSH (follicle stimulating hormone), concluded that only very low – if
any appreciable – amounts of BiPwere recoveredwithwild type versions
of the receptors. Folding defective mutant forms of the LH-receptor
however recruited BiP to a variable extent [32]. It is therefore conceivable
that the nascent A2A-receptor directs a chaperone other than BiP to
the pore.
Several proteins must cooperate to shield the nascent receptor from
the potentially toxic ER environment, where it may encounter and
aggregate with other unfolded proteins [33]. The receptor is therefore
trapped in a cage that is conducive to folding. This cage comprises
calnexin, and several other proteins including the oligosaccharde
transferases that co-translationally subject it to core glycosylation [34].
It appears that the oligosaccharide transferase complex per se already
assists in folding. Ribophorin I, a component of the oligosaccharide
transferase complex, is required for cell surface expression of the µ-opioid
receptor in a manner that appears to be calnexin-independent.
Ribophorin-Imay also recruit BiP to the µ-opioid receptor [35]. Sequentialtrimming of two glucose residues by glucosidases I and II allows for
subsequent recruitment of the lectin domain of membrane-bound
calnexin and its soluble counterpart calreticulin. The complex of calnexin
and ERp57 directs the appropriate protein-disulﬁde isomerase to support
formation of the crucial four disulﬁde bonds that connect the extracellular
loops. The ER quality control concept emphasizes the cycle between the
foldingsensorUDP-glucose-glycoproteinglucosyl transferase (UGGT)and
glucosidase-III. UGGT reglucosylates incompletely folded proteins and
thus drives their reassociationwith calnexin. Glucosidase III trims the last
glucose and thus precludes reassociation with calnexin.
There are two arguments that suggest that factors beyond the
glucosylation/deglucosylation cycle must be important to ascertain
quality control:
(i) apart from the lectin domain, the transmembrane domain of
calnexin also participates in caging: it can target membrane proteins
into ER-derived circular membarne bodies that have also been termed
organized smooth ER (OSER) membranes; the A2A-receptor is among
those GPCRs that are readily targeted to these OSER membranes [36].
(ii) From a conceptual viewpoint, it is important that the folding state
also be sampled on the cytoplasmic side. In other words, there must be
chaperones that attach to the C-terminus of the GPCRs because this
precludes premature export of incompletely folded proteins by blocking
access of the COPII-machinery (see below). There are several examples of
canonical chaperones and candidate chaperones that interact with the C-
terminus of GPCRs: DRiP78 (dopamine receptor-interacting protein of
78 kDa, a hsp40 relative) is themost prominent example. DriP78 binds to
the conserved C-terminal hydrophobic motif F(x)3F(x)3F [37]. The F(x)3F
(x)3Fmotif and relatedmotifs [(FN(X)2LL(X)3 L, F(X)6LLmotif] are found
in many GPCRs within the juxtamembrane portion of GPCRs. Over-
expression of DRiP78 causes intracellular retention of the A1-adenosine
receptor [18]. This effect can be rationalized by taking into account that
overexpression of DRiP78 shifts the equilibrium between folded and
partially folded state. The A1-adenosine receptor also binds hSC73 (heat
shock cognate protein 73). However, HSC-73 does not bind to the C-
terminus, but to the third intracellular loop of the A1-receptor [38]. At the
very least, the fact that twochaperones canbe recruited to thecytoplasmic
surface of the A1-adenosine receptor highlights the importance of
sampling the folded state on the intracellular face of the ER membrane.
An additional example of a chaperone from a different class is GEC1/
GABAARAPL (cloned from estrogen-stimulated endometrial glandular
epithelial cells/GABAA-receptor-associated protein like-1). GEC1 recog-
nizes a FPXXM/FPXM motif and acts a chaperone for κ-opioid receptors
and the f-splice variant of the EP3-receptor (E prostanoid receptor) [39].
Becauseof its verynature– it is amember of themicrotulubule-associated
proteins (MAP's)–GEC1mayalso provide for a link tomotor proteins. It is
worth noting in this context, that one of the A2A-receptor interactors of
unknown function is themicrotubule binding protein astrin. The reader is
referred to two excellent recent reviews for a more detailed account on
the role of general and dedicated chaperones in the folding of
GPCRs [40,41].
2.2. Moving out — a chaperone/COPII-exchange model
In order to leave the endoplasmic reticulum, the A2A-receptor must
engage the components of COPII (coat protein complex II)-machinery
[42,43]. This is achievedby theSAR1-dependent recruitmentof theSEC23/
SEC24 dimer to the cargo. Awell understood traditional ER exportmotif is
the diacidicmotif DXE, which has been studied in themodel cargo VSV-G
(the vesicular stomatitis virus glycoprotein). It is however clear that
SEC24-isoforms have several cargo binding sites [44,45] In addition,
mammalian cells have four isoforms of SEC24 (termed SEC24A-D). The
rules that governcargo selectionarenot knownbut there areexamples for
both, exquisite selectivity andpromiscuitywhenmodel cargoes are tested
[46]. In spite of the abundant number of GPCRs the cargo speciﬁcity has
not been tested for this class of proteins. However, the GAT1 (GABA-
transporter-1) and its relatives such as the dopamine transporter are
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from all previously identiﬁed contact sites [47].
A diacidic D330GE332-motif is present in the C-terminus of the A2A-
receptor (see Fig. 2). It is not clearwhether this is required forERexport. In
fact, the truncated version A2A-receptor(1-311) is still exported to the cell
surface, albeit at lower efﬁciency [9]. The diacidic motif is present in all
mammalian orthologs, but is absent in the two A2A-receptors that are
expressed in zebra ﬁsh. In addition, experiments with vasopressin V1b/V3
receptor indicates that the distal diacidic motif is dispensable but that the
conserved phenylalanine-basedmotif [FN(X)[2]LL(X)[3]L] is essential for
ER export [48]. It has been difﬁcult to differentiate between effects on ER
export per se and on folding defects. Mutationswithin the phenylalanine-
based motifs disrupt both [49,50]. It is obvious that ER quality control
safeguards against the export of an unfolded protein. Nevertheless, it
remains unclear why mutations within the C-terminus affect the folding
of hydrophobic core. As mentioned earlier, in the crystal structure of the
A2A-receptor helix 8 is stabilized by interactions with helix 1 and helix 7
[7]. Conversely, helix 8 of the C-terminus can bepostulated to stabilize the
hydrophobic core. Experiments have not been carried out systematically
with the A2A-receptor to test this hypothesis. However, observationswith
theA1-receptor canbe readily extrapolated, because the residues involved
are conserved:mutations of the tyrosine in the NPXYmotif of TM7 and of
the candidateп-п-stack pairing phenylalanine (in helix 8) impede folding
of the A1-receptor [18]. The phenotype can be rescued by pharmacocha-
perone and the rescued receptor is rapidly routed via ERGIC and Golgi to
the cell surface [18]. This observation indicates that the phenylalanine is
not the docking site for a SEC24 isoform. It is also worth noting that
residues beyond the immediate juxtamembrane region are also involved
in stabilizing the folded structure of the A1-adenosine receptor [17].
Taken together, these observations can be pieced into the following
model (Fig. 2). The nascent C-terminus of a GPCR is trapped by a
chaperone (presumably of theHSP family). Its ﬁnal release coincideswith
the adoption of the folded structure. As long as the C-terminus is engaged
by the chaperone access of the cognate SEC24-isoform is precluded. Thus,
the exchange of the SEC24-isoform for the heat-shock protein prevents
the premature recruitment of a partially folded protein into the COPII-
vesicle. Poorly folded membrane proteins are prone to self-aggregation
and to aggregate with other membrane proteins. It is therefore not
surprising that quality control at the ER level is very stringent by
monitoring the folded state at both the luminal and the cytoplasmic site.
For the A2A-adenosine receptor, the equilibrium between ER-export and
ERAD (ER associated degradation) can be shifted. The A2A- adenosine
receptor is subject todeubiquitinationbyUSP4.This rescues receptors thatFig. 2. The chaperone/COPII-exchange model: a (yet unidentiﬁed) heat shock protein chape
sites (ERES) and recruitment of the (bow tie shaped) Sec23/Sec24 dimer (white=Sec24, blu
chaperone. The ER quality control is apparently overprotective: the A2A-receptor is ubiquitin
deubiquinating enzyme USP4 relieves this stringent quality control; removal of ubiquitin shif
the chaperone and the Sec34/Sec24-dimer precludes the premature recruitment of partiallhavebeen targeted fordegradation indicating that the cell surface levels of
the receptor depend on the cellular level of this enzyme [22].
Apart fromUSP4, there is another candidate interactor, namely14-3-
3τ/θ that may also play a role at an early stage in the secretory path-
way. 14-3-3 proteins are adapters for phospho-serine and phospho-
threonine residues, however they can also bind to basic motifs such as
RKR that – when exposed – function as ER retention motif [51]. There
is no RKR motif in the A2A-receptor and there are none of the canonical
14-3-3 binding sites (RSXSPO4XP, RXXX SPO4XP) but the binding of
14-3-3β to KCN3-potassium channels also occurred on a site that did
not comprise a classical motif [52]. It is therefore conceivable that
14-3-3τ/θ is also required to mask dibasic retention signals of which
there is one in the C-terminus of the A2A-receptor. Signals are required
to afford the trafﬁcking of A2A-receptor through subsequent compart-
ments, i.e., from the ERGIC to cis-Golgi, through the Golgi stacks and
from the trans-Golgi network to the cell surface but they have not been
identiﬁed in the A2A-receptor. A dileucine motif, which is associated
with sorting ofmembrane proteins from the trans-Golgi network (TGN)
to the basolateral membrane of epithelial cells, can also be foundwithin
the C-terminus of the human A2A-receptor (Fig. 1). Its role has not been
veriﬁed for the A2A-receptor but it appears unlikely to be important, it
is for instance absent in the rat and bovine sequence.
3. Partners engaged to the mature receptor at the cell surface
At the cell surface, theA2A-receptor engages its cognate heterotrimeric
G protein, the Gαs βγ-subunit complex, which is larger in size than the
receptor per se. In addition, it can interact with its C-terminus with
additional signalling proteins (ARNO, translin-X, calmodulin, NECAB2)
and adapters (SAP102, α-actinin-1). For several reasons it is clear that
bindingof all potential interactionproteinsdoesnotoccur simultaneously.
(i) Not all proteins are expressed in all cell types to the same extent (e.g.,
neuronal proteins are restricted to cells of neural crest origin); (ii) the size
of the individual binding partners makes it unlikely that the C-terminus
can accommodate several partners simultaneously. This is highlighted by
the overlapping binding sites for ARNO,α-actinin and calmodulin (Fig. 1).
Thus, individual interactions are likely to be only transient. (iii)
Preliminary data from our group indicates that ARNO is recruited to the
plasma membrane upon receptor stimulation. However prolonged
activation reduces the amount ofmembrane associatedARNO. In contrast,
a dominant negative variant (incapable of activating ARF6) shows
sustained membrane recruitment. (iv) The binding afﬁnity of NECAB2 is
dependent on the presence of Ca2+.rone (HSP) engages the carboxyl terminus of the A2A-receptor. Movement into ER exit
e=Sec23, liganded to GTP loaded SAR1 in red) is contingent on the prior release of the
ated (red branches) by an E3-ligase and subsequently degraded by the proteasome. The
ts the equilibrium in favour of the ER export pathway. Themutually exclusive binding of
y folded receptors into a nascent COPII-vesicle.
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SAP102 is the human homolog of the disc large gene product of
Drosophila melanogaster and belongs to the family of membrane
associated guanylate kinase-like domain (MAGUK) proteins. MAGUK
proteins are important components of synapses, because they orches-
trate synaptic organization by anchoring transmembrane and cytoplas-
mic proteins. All members share a homologous domain arrangement;
they are composed of three PDZ domains, a SRC homology 3 (SH3)
domain and a C-terminal GUK domain lacking catalytic activity. SAP102
is highly enriched in the cell body of neurons and at the postsynaptic
density of excitatory synapses. During synaptogenesis, SAP102 is
upregulated within the ﬁrst two postnatal weeks on both, mRNA and
protein level [53], and controls trafﬁcking of NMDA receptors. Onemain
function of SAP102 is to anchor membrane proteins to the plasma
membrane by forming multiprotein complexes. According to its
proposed role as scaffold protein, several interacting partners for
SAP102 have been identiﬁed as NMDA receptors as well as 5-HT2A and
5-HT2C receptors and kainate receptors domain [53–56]. Tethering to
SAP proteins also affects trafﬁcking of receptors and other membrane
proteins: indeed, PSD95/SAP90 inhibits the internalization of NMDA
receptors and of glycine transporters [57,58]. Finally, SAP proteins do
not only interact with receptors, but alsowith proteins involved in their
cognate signaling cascades [59,60]. As an example PSD-95/SAP90
inﬂuences the MAP kinase pathway through binding of SynGAP, a
GTPase activating protein (GAP) for RAS [60].
In striatopallidal neurons, both, A2A receptors and SAP102 are highly
enriched at postsynaptic sites. Our unpublished work revealed an
interaction between these two proteins, the binding occurs at the distal
portion of the C-tail. The interaction with SAP102 decelerates mobility of
the receptor.
3.2. α-Actinin
α-Actinin is a major F-actin cross-linking protein. So far, four
isoforms have been identiﬁed; α-actinin-1 and -4 are present in non-
muscle-tissue and are capable of binding to Ca2+ ions whereas α-
actinin-2 and -3 are enriched in muscle tissue and fail to bind Ca2+
ions. Each actinin-protein carries an N-terminal actin binding domain
containing two calponin homology (CH-) domains. This is followed by
a central region composed of four spectrin repeats and C-terminal EF-
hand motifs that allow for Ca2+ ions binding. A subset of EF domains,
though, is devoid of Ca2+ binding capacity [61]. More recently, it has
also been appreciated that α-actinin binds partners other than
cytoskeletal proteins. Apart from ion channels, GPCRs. have also
been found to recruit α-actinin. This includes the A2A-receptor which
binds α-actinin-1 and is thereby tethered to the cytoskeleton [26].
The other interaction partner is the metabotropic glutamate receptor-
5b (mGluR5b) [62]. The observations suggest opposite roles for α-
actinin-1: it promotes cell surface localization of and signalling by
mGluR5b [62] but accelerates internalization of the A2A-receptor [26].
The latter observation is interesting for the following reasons: (i) in
most instances, the internalization of the A2A-receptor is difﬁcult to
observe (see e.g., 20,24). Discrepancies between internalizing and
non-internalizing situations may be rationalized by assuming that the
level of α-actinin-1 determines the propensity of the A2A-receptor to
internalize. There is precedent for a limiting inﬂuence of the actin
cytoskeleton on receptor internalization: the closely related CRF
(corticotropin releasing factor)-receptors-1 and -2 differ by their
ability to undergo agonist-triggered internalization although arrestins
are readily recruited to both receptors: CRFR1 – but not CRFR2 – is
readily internalized. This difference is abolished, if the cells are
pretreated with latrunculin A to disrupt the cortical actin meshwork.
Under these conditions, agonist challenge triggers a redistribution of
CRFR2 from the cell surface into rab5-positive vesicles [63]. (ii) The
restricted collision coupling of A2A-receptor (see above) may also berelated to tethering to the actin cytoskeleton. It would be interesting
to explore if mutants that fail to bind α-actinin-1 differ in their ability
to sample large areas of the cell surface. Latrunculin A does, in fact,
shift the concentration curve for agonist induced cAMP accumulation
by the CRFR2 to the left [63]. However, latrunculin A does not affect
ensemble receptor mobility of the A2A-receptor sampled by FRAP,
ﬂuorescence recovery after acceptor photobleaching and this also true
for a C-terminally truncated version of the receptor where the
presumed binding site for α-actinin-1 is severed [20,24].
3.3. Calmodulin
A2A-receptors andD2-dopamine receptors formheteromers; these are
thought to be important formediating themutual antagonism that can be
observedwhen these receptors are co-expressed in the intermediate size
spiny striatal neurons. Both, A2A- andD2-receptors reside postsynaptically
in the neurons of the indirect (striatopallidal) pathway, where D2-
receptor activation facilitates while A2A-receptor activation impedes the
initiation of a motor programme [64]. Calmodulin binds to the amino
terminal end of the third intracellular loop and inhibits G protein
activation by the receptor [65]. Calmodulin binds to the segment adjacent
to the α-actinin-1 binding site between arginine291 and R300 (marked in
blue in Fig. 1), i.e., in the juxtamembrane portion within helix 8 [66]. A
second more distal site that comprises a phosphorylated residue
(serine374) was also proposed [67]. While binding of calmodulin to D2-/
A2A-receptor heteromers can be visualized in living cells by biolumines-
cence resonance transfer (BRET) and related methods, it is not clear,
whether this is association is required to stabilize the dimer. D2-receptors
form constitutive dimers even with truncated versions of the A2A-
receptors [24] and this does not require calcium entry. In the absence of
calcium, calmodulinbind to its cognatemotif on theD2-receptorwithonly
very low afﬁnity [65]. In addition, it is difﬁcult to test the functional
consequence of calmodulin binding in intact cells, because all cells express
abundant amounts. Many calmodulin antagonists are very potent D2-
receptor antagonists.
3.4. Necab2
Neuronal Ca2+-binding protein 2 (NECAB2) is the third calcium
binding protein that interacts with the C-terminus of the A2A-receptor
[68]. It has two relatives NECAB1 and NECAB3; apart from their
(atypical) EF-hand, the function of these proteins is poorly under-
stood. NECAB2 binds to the C-terminus of the A2A-receptor in a
calcium-dependent manner. Surprisingly, binding is disfavoured in
the presence of calcium. This should allow the C-terminus of the
receptor to act as a coincidence detector and signal integrator,
because binding of NECAB2 enhances signalling via the A2A-receptor.
In the striatopallidal neurons where NECAB2 and the A2A-receptor are
coexpressed NECA2B ought to accentuate activity-dependent cAMP-
oscillations: because the predominant adenylyl cyclase isoforms in
the striatum are the calcium-inhibited isoforms V and VI, calcium
entry ought to inhibit both the catalytic moiety and the ability of the
A2A-receptor to stimulate these adenylyl cyclases via Gαs. Thus, the
cAMP response of neurons subjected to repetitive electrical spikes
ought to differ from that of neurons that are electrically quiescent.
With the advent of FRET-based cAMP detectors this hypothesis can be
readily tested [24].
3.5. Translin associated protein X
Translin associated protein X (TRAX) is another potential interaction
partner and contributes to PC12 cell differentiation in a Gs/cAMP-
independent manner [25]. Originally, TRAX was recognized as binding
protein for translin and translin proteins were recognized as regulators
of cell cycle control [69]. More recently, translin and TRAX have been
recognized as RNA-bindingproteins thatmay regulate the accumulation
Fig. 3. Segregated signalling pathways of A2A-receptor: the canonical Gs-dependent activation of adenylyl cyclase results in the stimulation of cAMP effectors (i.e., protein kinase A/
PKA, Epac, the exchange protein activated by cAMP, which catalyzes the GTP-loading of Rap1, and the opening of cyclic nucleotide gated channels/CNG). This may result in transient
calcium increases, which are sensed by calmodulin and of NECAB2 (not shown, see text). In their calcium-loaded state these proteins may affect the capacity of the receptor to
interact with ARNO (see Fig. 2 and text). Activation of ARNO can take place in a different membrane compartment (indicated by red lipids), does not require coupling to G proteins
and leads to sustained stimulation of MAP kinase/ ERK1/2 via RAS/RASF1/MEK1. The link between ARF6 and RAS is not known. There is at present no experimental evidence
(indicated by question marks) that the agonist-liganded A2A-receptor stimulate the additional ARF6-dependent pathways (activation of phospholipase D2 and of PIP5-kinase; actin
remodelling via RAC, increased endocytosis).
1355S. Keuerleber et al. / Biochimica et Biophysica Acta 1808 (2011) 1350–1357of dendritic mRNA in a manner similar to Staufen [70]. It is obvious that
these effects cannot be fully recapitulated in PC12 cells because in these
cells neurite extensions do not correspond to a dendritic compartment.
Thus it remains unclear, how these activities relate to TRAX binding to
the A2A-receptor C-terminus.
3.6. ARNO/cytohesin-2
ARNO/cytohesin-2 is a guanine nucleotide exchange factor that
catalyzes the replacement of GDP by GTP on small monomeric G
proteins of the ARF-family. Cytohesins comprise a subfamily within
the mammalian guanine nucleotide exchange factors (GEFs) for ARF-
isoforms. They are smaller in size (∼400 amino acids) than the large
exchange factors of the BIG- (∼1800 amino acids) & EFA-families
(∼1000 amino acids). Members of the cytohesin family include (i)
cytohesin-1, which was originally identiﬁed as activator of integrin-
mediated adhesion, and predominantly expressed in leukocytes [71];
(ii) GRP1/ARNO3 [72], (ii) ARNO4 and (iii) ARNO/cytohesin-2 (with a
molecular weight of 47 kDa) [73]. All four proteins share the same
organization; a central SEC7 domain with high homology to the yeast
protein is ﬂanked by an N-terminal coiled–coiled domain, and a C
terminal PH-domain. The former serves as protein interaction site
(see below), whereas the latter is responsible for anchoring ARNO to
the plasma membrane. Within the Sec7 domain, a conserved
embedded glutamate residue at position 156 is responsible for GDP/
GTP exchange on ARF proteins. ARF GTP-binding proteins belong to
the RAS superfamily of small monomeric G proteins. They were
originally identiﬁed as co-activators for cholera toxin-catalyzed ADP-
ribosylation of Gαs and soon recognized to be GTP-binding proteins
themselves [74]. Similar to other GTP-binding proteins ARF proteins
cycle between a GDP-bound (inactive) and a GTP-bound (active)
state. This cycling is regulated by two distinct classes of proteins. GTP
loading is stimulated due to the action of GEFs; whereas GTP
hydrolysis by GTPase activating proteins (GAPs). Accordingly substi-tution of this glutamate with lysine (E156K mutant) abrogates
catalytic activity [75]. In vivo ARNO/cytohesin-2 activates ARF6 rather
than ARF1, whereas in-vitro data suggest activation of both proteins
[75]. In the presence of [4,5] PIP2 nucleotide exchange is accelerated.
ARNO binds to the proximal portion within the C-terminus of the
A2A receptor. This interaction is responsible for sustained stimulation
of MAP kinase by the A2A receptor [23]. To trigger this pathway, the
A2A-receptor need not engage its cognate G protein Gs (Fig. 3); in fact,
activation of ARNO can take place in cholesterol-depleted membranes
which precludes activation of Gs-dependent cAMP accumulation by
the A2A-receptor [24]. At the very least this observation proves
that the A2A-receptor can signal in a G protein-independent manner.
In addition, it suggests that activation of Gs and of ARNO may take
place in different membrane microdomains [24]. Cholesterol-rich
membrane microdomains are essential for the activation of adenylyl
cyclase via Gs, whereas MAPK stimulation is not affected by
cholesterol depletion.
ARF6 is recruited to the plasma membrane by a variety of stimuli
including GPCR agonists [76]. Activation of ARF6 by ARNO/cytohesin-
2 and EFA6 (exchange factor for ARF6) leads to activation (Fig. 3) of
(i) phospholipase D2 (PLD2), (ii) Rac1 and (iii) PIP5 kinase [77]. These
downstream effectors orchestrate a number of cellular responses.
Activation of PLD2 leads to the formation of phosphatidic acid (PA),
which in turn activates PIP5 kinase. Thus, PIP5 kinase activation by
ARF6 occurs via both, a direct and an indirect patwhay. PIP5 kinase
produces/replenishes phosphatidylinositol 4,5-biphosphate (PIP2).
Local accumulation of PIP2 promotes clathrin-regulated endocytosis
andmembrane trafﬁcking. ARF6 is implicated in endocytosis on apical
[78,79] and basolateral membranes [80]. ARF6 has been demonstrated
to directly interact with components of the clathrin coat, namely AP-2
and with clathrin [81]. Upon stimulation of angiotensin AT1 receptors,
ARF6 is activated and forms a complex with AP2 and clathrin [81]. In
addition, ARF6 also regulates clathrin and caveolin independent
endocytosis [82]. The pronounced effects of ARF6 on membrane
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the cell surface (see below). It remains an enigma how the A2A-
receptor signals via ARNO and ARF6 but escapes internalization.
4. Desensitization of the A2A-receptor and the twilight zone
Desensitization refers to the well-known phenomenon that
responses triggered by G protein coupled receptors fade when the
receptor is subjected to sustained or repeated agonist stimulation. This
process includes GPCR phosphorylation, recruitment of β-arrestins
which precludes coupling to G proteins and adapter proteins, and – in
many instances – removal of GPCRs from the cell surface by endocytosis.
Upon sustained activation, the A2A receptor undergoes homologous
desensitization. However, receptor number does not change [83,84].
The receptor undergoes rapid phosphorylation at threonine 298 [85].
The responsible kinase is GRK2 [86]. Depletion of GRK2 by either
overexpression of a dominant negative version [86] or by selective
knock-out with siRNA [87] reduces desensitization of the A2A-receptor.
A large portion of the C-terminus is dispensable for desensitization:
removal of the last 95 amino acids results in a truncated receptor that
still undergoes desensitization.
Insights into the eventual fate of the A2A-receptor have been obscured
by the fact that the A2A-receptor internalizes to a very limited extent. This
limits our ability to track the fate of the protein when destined for
destruction. Given that the receptor is subject to ubiquitination at level of
the ER, it is also safe to assume that there are (i) E3 ubiquitin ligases that
recognize the receptor at the cell surface or in endocytic compartment;
(ii) sorting proteins that route the receptor either to recyling endosomes
or late endosomes/lysosomes; (iii) these interactions arepredicted to take
place on the C-terminus of the receptor.
5. Concluding remarks
Many aspects of the A2A-receptor remain puzzling. Among themany
unsolved questions is the restricted collision coupling, which has been
described more than 30 years ago [88,89]. Restricted collision coupling
may be the result of tight coupling between receptor and Gs [90,91].
However, in spite of structural insights at atomic resolution, it unclear,
why and how A2A-receptor and Gs are tightly coupled. It is also unclear
how the receptor escapes from internalization. Nevertheless, the
growing list of interactors justiﬁes the conjecture that the key to
unravelling these enigmas is the carboxyl terminus of the receptor.
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